- Home
- PSNL vs TLRY Comparison
PSNL vs TLRY Comparison
Compare PSNL & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | TLRY |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 688.9M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PSNL | TLRY |
|---|---|---|
| Price | $6.68 | $5.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $12.20 | ★ $72.33 |
| AVG Volume (30 Days) | 2.1M | ★ 7.0M |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $15.34 | $8.79 |
| Revenue Next Year | $41.46 | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.84 | $0.36 |
| 52 Week High | $11.50 | $15.70 |
Technical Indicators
Market Signals| Indicator | PSNL | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 34.93 |
| Support Level | $5.81 | $1.12 |
| Resistance Level | $7.04 | $7.01 |
| Average True Range (ATR) | 0.52 | 0.27 |
| MACD | 0.15 | -0.07 |
| Stochastic Oscillator | 75.49 | 12.80 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.